In December, Professor Erika Lietzan spoke at a pharmaceutical law conference hosted by the CREDIMI, a center for research relating to markets and international investment, at the school of law at the Université de Bourgogne in Dijon, France.

She presented her research examining the impact of pharmaceutical regulation on effective patent life and discussed its implications for restoration of patent terms in the United States and Europe (pursuant to a “supplementary protection certificate,” or SPC).  She was joined by Jean-Christophe Halloux, a professor of private law at the Université Paris II and specialist in intellectual property law and health law.

The conference program may be viewed here.

While in France, she also taught a two-hour class on the U.S. pharmaceutical market to law students at the Université de Bourgogne, focusing not only on FDA regulation but also on state regulation of pharmacies and physicians, and rules and practices relating to the pharmaceutical supply chain, and exploring how the U.S. paradigm differs from the European and French paradigms.